Roka Bioscience Wraps Up Initial Public Offering on NASDAQ
Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, on July 17 announced its initial public offering of five million shares of its common stock at $12 per share, before underwriting discounts. All of the common stock was offered by Roka Bioscience.
Roka Bioscience also has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price. The shares began trading on the NASDAQ Global Market on July 17 under the ticker symbol "ROKA," and the offering was slated to close yesterday.
BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow Life Sciences are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 16. When available, copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or via email, at email@example.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, via email at firstname.lastname@example.org, or by phone at (800) 808-7525, ext. 4814.